Ingrid A.M. Mandjes - Concepedia

Author

Ingrid A.M. Mandjes

Also Known As

I A Mandjes, I Mandjes, I. A. M. Mandjes, I. Mandjes, I.A. Mandjes, I.A.M. Mandjes, INGRID MANDJES, Ingrid A. Mandjes, Ingrid A M Mandjes, Ingrid A Mandjes

114

Publications

2.7K

Citations

H-Index

Concepts

All Affiliations

The Netherlands Cancer Institute Oncode Institute Reinier de Graaf Hospital Ziekenhuis Groep Twente University Medical Center Utrecht

About

Ingrid A.M. Mandjes is an author at The Netherlands Cancer Institute specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	14	1.7K
2	Health Sciences	3	3	94
3	Engineering	1	1	60
4	Biology	1	1	33
5	Environmental Engineering	1	1	60

Ingrid A.M. Mandjes

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial Leonie Voorwerk, Maarten Slagter, Hugo M. Horlings, Nature Medicine Tumor ImmunologyBreast OncologyCancer ImmunosurveillancePd-1 BlockadeMedicine	2019	854
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial Mette S. van Ramshorst, Anna van der Voort, Erik van Werkhoven, The Lancet Oncology Breast OncologyOncologyDual Her2 BlockadePharmacologyBreast Cancer	2018	413
Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel Jetske M. Meerum Terwogt, W.W. ten Bokkel Huinink, Jan H.M. Schellens, Anti-Cancer Drugs	2001	276
Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual<i>ERBB2</i>Blockade in Patients With<i>ERBB2</i>-Positive Breast Cancer Anna van der Voort, Mette S. van Ramshorst, Erik van Werkhoven, JAMA Oncology	2021	130
Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response Esther H. Lips, Lennart Mulder, Jorma J. de Ronde, Breast Cancer Research and Treatment	2013	114
Neoadjuvant chemotherapy in ER+ HER2− breast cancer: response prediction based on immunohistochemical and molecular characteristics Esther H. Lips, Lennart Mulder, Jorma J. de Ronde, Breast Cancer Research and Treatment Breast OncologyMedicineImmunologyPathologyResponse Prediction	2011	85
Loss of heterozygosity in Wilms' tumors, studied for six putative tumor suppressor regions, is limited to chromosome 11. Marcel M. A. M. Mannens, Peter Devilee, Jet Bliek, PubMed Dna MarkersSomatic VariantCancer PathologyCytogeneticsGenetic Disorder	1990	82
Toxicity grading systems H. Franklin, Giovanni Simonetti, Anne-Charlotte Dubbelman, Annals of Oncology EngineeringPredictive ToxicologyEnvironmental EngineeringForensic ToxicologyToxicology Testing	1994	60
A simple system for grading the response of breast cancer to neoadjuvant chemotherapy Sjoerd Rodenhuis, Ingrid A.M. Mandjes, Jelle Wesseling, Annals of Oncology Tumor BiologyBreast OncologyMedicineCancer ManagementSimple System	2009	54
High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial. Jan B. Vermorken, W.W. ten Bokkel Huinink, Ingrid A.M. Mandjes, PubMed	1995	50

Page 1